

Special Issue

Personalized Medicine in Cancer Therapy: Mechanism, Approaches and Techniques

Message from the Guest Editors

Personalized medicine differs from standard treatment approaches due to the identification of factors (e.g., molecular features, phenotypes, environment, biomarkers) making individual patients eligible for a specific treatment. The tumor microenvironment (TME) is attracting growing attention in cancer research. This highly complex network composed of non-tumor cells, extracellular matrix (ECM) proteins, and secreted factors modulates and is modulated by malignant cells. The dynamic landscape of the TME impacts on treatment outcome, leading to therapy resistance, and contributes to tumor heterogeneity, which represents a critical factor driving tumor progression and dissemination. This Special Issue will host review, opinion, short communication, and research articles focusing on personalized medicine—exploring strategies to model and target the TME. We particularly welcome articles integrating preclinical models (e.g., 3D models, organoids), omics (e.g., metabolomics, proteomics, genomics), and bioinformatics analyses. Special attention will be given to cross-disciplinary approaches involving clinicians, biologists, chemists, physicists, etc.

Guest Editors

Dr. Michele Zanoni

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"—IRST S.r.l.,
47014 Meldola, Italy

Dr. Michela Cortesi

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.,
47014 Meldola, Italy

Deadline for manuscript submissions

closed (30 June 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/92823

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).